Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.
Yoshiaki YamamotoJunji YatsudaMototsugu ShimokawaNakanori FujiAkihiko AokiShigeru SakanoMitsutaka YamamotoAkinobu SugaYasuhide TeiSatoru YoshihiroSeiji KitaharaKazuhiro NagaoKimio TakaiYoriaki KamiryoJumpei AkaoShiro YamaguchiKazuo ObaTomoyuki ShimabukuroHiroaki MatsumotoTomomi KambaHideyasu MatsuyamaPublished in: International journal of clinical oncology (2020)
This pretreatment risk stratification may be used for estimating the OS and ORR of patients with advanced UC treated with pembrolizumab. If changes in NLR in response to pembrolizumab treatment improve, pembrolizumab should be continued.
Keyphrases